secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125353
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics Q3 net loss $15.1M ($0.21/share); cash $267.8M funds into mid-2026
--------------------------------------------------------------------------------

- Net loss from continuing and discontinued ops $15.1M vs $10.4M YoY; basic loss per share $0.21.
- Cash, equivalents and short-term investments $267.8M (Sep 30, 2024) vs $9.2M at Dec 31, 2023.
- R&D expense surged 114% to $12.0M; G&A expense up 56% to $7.0M; no product revenue.
- Phase 1/2a trials advancing: VMT-α-NET and VMT01; combo cohort with nivolumab open.
- Manufacturing capacity expanded: second cGMP facility in Somerset, NJ and three new buildings purchased.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017024125353/0000950170-24-125353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017024125353/catx-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer